{
  "actions": [
    {
      "acted_at": "2015-05-14", 
      "committees": [
        "HSIF"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Referred to the House Committee on Energy and Commerce.", 
      "type": "referral"
    }, 
    {
      "acted_at": "2015-05-15", 
      "in_committee": null, 
      "references": [], 
      "text": "Referred to the Subcommittee on Health.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "hr2338-114", 
  "bill_type": "hr", 
  "by_request": false, 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF"
    }, 
    {
      "activity": [
        "referral"
      ], 
      "committee": "House Energy and Commerce", 
      "committee_id": "HSIF", 
      "subcommittee": "Subcommittee on Health", 
      "subcommittee_id": "14"
    }
  ], 
  "congress": "114", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2015-05-14", 
  "number": "2338", 
  "official_title": "To amend the Federal Food, Drug, and Cosmetic Act to provide for the development and use of patient experience data to enhance the structured risk-benefit assessment framework, and for other purposes.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "hr6-114", 
      "reason": "related", 
      "type": "bill"
    }
  ], 
  "short_title": null, 
  "sponsor": {
    "district": "16", 
    "name": "Pitts, Joseph R.", 
    "state": "PA", 
    "thomas_id": "01514", 
    "title": "Rep", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2015-05-14", 
  "subjects": [
    "Administrative law and regulatory procedures", 
    "Department of Health and Human Services", 
    "Drug safety, medical device, and laboratory regulation", 
    "Health", 
    "Health information and medical records", 
    "Medical research", 
    "Research administration and funding"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced", 
    "date": "2015-05-14", 
    "text": "This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish processes under which: (1) an entity seeking to develop patient experience data may submit initial research concepts for feedback; (2) the FDA may request or receive from such an entity draft guidance documents, data, and summaries and analyses of data; and (3) patient experience data may be considered in the risk-benefit assessment of a new drug.\n\n\u201cPatient experience data\u201d is data collected by patients or others that is intended to facilitate the FDA's risk-benefit assessments, including information about the impact of a disease or a therapy on patients' lives.\n\nThe FDA must convene workshops and publish guidance on the patient experience data processes described above."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "To amend the Federal Food, Drug, and Cosmetic Act to provide for the development and use of patient experience data to enhance the structured risk-benefit assessment framework, and for other purposes.", 
      "type": "official"
    }
  ], 
  "updated_at": "2016-06-25T06:43:05-04:00", 
  "url": "http://thomas.loc.gov/cgi-bin/bdquery/z?d114:HR2338:@@@L&summ2=m&"
}